Sufrexal P (Ketanserin, Benzocaine)

Active Ingredient: Ketanserin, Benzocaine
Dosage: 78 g
Route of Administration: Local
Dosage Form: Gel
Quantity per package: 1 unit
Availability: Out of stock

Why is Sufrexal P not sold  in the USA?

In the USA, Sufrexal P is not used, primarily because of concerns related to the safety profile of Benzocaine, which has been linked to risks of methemoglobinemia. The FDA has stringent regulations regarding products containing Benzocaine, especially for certain populations like infants and children.

Similar Treatments Available in the USA

There is no currently available gels helping to overcome the described symptoms but we’ve collected a list with general pain relief options effective in the following symptoms.

Pain Relief Medications (General):

What is Sufrexal P?

Sufrexal P is an analgesic that contains ketanserin and benzocaine. It is used for temporary relief of inflammation and pain in the oral cavity: mouth, tongue, and cheeks. The gel is applied to the mouth or gums in methemoglobinemia. Unfortunately, Sufrexal P is out of stock currently.

Indications

Sufrexal P gel is prescribed to relieve pain and inflammation of the oral cavity.

Dosage and administration

The dose of Sufrexal P will differ for individual patients. Follow the physician’s recommendations or instructions for use. The following information includes only the average doses of Sufrexal P.

For topical dosage forms in the diagnosis like pain in the mouth and oral cavity:

• adults, teenagers, and children 2 years old and over, apply three or four times a day to the affected area.
• toddlers: usage and dose must be specified by your healthcare physician.

Sufrexal P is typically available in a gel form. The recommended dosage involves applying a small amount of gel directly to the affected area in the mouth 2-3 times a day, or as directed by a healthcare provider. It should be used minimally and only as needed due to the presence of Benzocaine, which can cause systemic effects if overused.

Popularity and Use in Specific Countries

Sufrexal P is popular in countries with less stringent regulations on medications containing Benzocaine. These countries often include regions in Latin America and some parts of Asia where there is a higher prevalence of oral health issues that are not immediately addressed by healthcare services, making topical treatments like Sufrexal P valuable for immediate pain relief and inflammation management.

Contraindications

• Pregnancy;
• Lactation;
• Hypersensitivity to the drug components.

Side Effects

1. Local Irritation: Some individuals may experience irritation at the site of application, such as burning, stinging, or itching.
2. Allergic Reactions: Allergic reactions to any component of Sufrexal P can occur, leading to symptoms like rash, itching, swelling, or difficulty breathing. Seek medical attention immediately if any allergic reaction is suspected.
3. Prolonged Use Side Effects: Long-term use or excessive application of corticosteroids like prednisolone can lead to skin thinning, stretch marks, increased hair growth, and potential systemic effects if absorbed through the skin.
4. Ocular Side Effects: If Sufrexal P comes into contact with the eyes, it can cause irritation, burning, blurred vision, or other visual disturbances.
5. Secondary Infections: Prolonged use of antibiotics like neomycin and polymyxin B can lead to the development of secondary infections by antibiotic-resistant organisms or fungi.
6. Systemic Absorption: While topical application minimizes systemic absorption, it’s still possible, especially with prolonged use or over large areas of skin. This can potentially lead to systemic side effects associated with corticosteroids, such as adrenal suppression or Cushing’s syndrome.

Interactions

1. Other Topical Medications: Using Sufrexal P with other topical medications, especially those containing corticosteroids or antibiotics, can increase the risk of local side effects or interfere with their effectiveness.
2. Systemic Corticosteroids: Concurrent use of Sufrexal P with systemic corticosteroids can increase the risk of systemic corticosteroid side effects.
3. Immunosuppressants: Since corticosteroids can suppress the immune system, concurrent use with other immunosuppressant medications can increase the risk of infections.
4. Neuromuscular Blocking Agents: There is a theoretical risk of increased neuromuscular blockade when neomycin and polymyxin B are used with neuromuscular blocking agents.
5. Live Vaccines: The immunosuppressive effects of corticosteroids may reduce the effectiveness of live vaccines. Therefore, it’s generally recommended to avoid live vaccines during treatment with Sufrexal P.
6. Other Ototoxic Drugs: Neomycin and polymyxin B are known to have ototoxic effects. Concurrent use with other ototoxic drugs, such as certain antibiotics or loop diuretics, may increase the risk of hearing loss or balance problems.